Seoul National University Bundang Hospital (SNUBH)
Glioma treatment cost in the Republic of Korea typically begins with a consultation with an oncologist ranging from $28 to $100, while primary surgical options like a craniotomy run from $16,500 to $38,000. Total expenses depend on the tumor stage, hospital tier, and necessity for specialized radiation like Gamma Knife, which costs $13,500 to $19,200. Patients often see 30-50% savings compared to the US. Top treatment centers are located in Seoul.
Typical Glioma Treatment Costs in Republic of Korea
Bookimed Expert Insight: Patients seeking high-precision care should prioritize Seoul's digitalized "Big 5" hospitals. Seoul National University Hospital (SNUH) is ideal for complex cases. It reports the highest cancer treatment statistics in the country. For error-prevention, SNUBH uses the BESTcare digital system. Severance Hospital offers JCI-accredited safety for international neurosurgery patients. Korea University Anam Hospital is best for those requiring advanced robotic-assisted surgical techniques.
| Republic of Korea | Turkey | Austria | |
| Gamma Knife | from $13,500 | from $6,300 | from $32,000 |
| Craniotomy | from $16,500 | from $5,650 | from $20,000 |
| Chemotherapy for breast cancer | from $19,200 | from $1,200 | from $15,000 |
| Stereotaxic radiosurgery | - | from $4,500 | from $17,000 |
| Resection of glioma | - | from $24,860 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Glioma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Glioma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Glioma treatment journey.
The doctor is a leading neurologist in South Korea, specializing in epilepsy treatment. Currently, the doctor serves as the Head of the Neurology Department at Yonsei Severance Hospital.
The doctor graduated from Yonsei University College of Medicine and is an active member of several professional organizations, including The Korean Epilepsy Society, The Korean Neurological Association, and The Korea Medical Association.
Dr. Kim Jin is a colorectal surgeon at Korea University Anam Hospital in Seoul. He is the Vice President of the Korean Association of Robotic Surgeons. Dr. Kim represents South Korea on the board of the Asia Pacific Endo-Lap Surgery Group. He performs surgical demonstrations for medical faculties in Hong Kong and Singapore.
Seoul National University Hospital (SNUH), Asan Medical Center, and Severance Hospital are the top facilities for glioma treatment in Korea. These JCI-accredited and Newsweek-ranked centers utilize Gamma Knife and multidisciplinary brain tumor teams. They focus on maximal safe resection and precise molecular pathology testing.
Bookimed Expert Insight: While prestigious names like SNUH are popular, Gangnam Severance provides specialized neurosurgery within a more accessible setting. Data shows that major Korean tertiary centers serve millions of patients. This makes speed of admission a critical factor. For glioma, choosing a JCI-accredited facility that can quickly assemble a surgical team often outweighs the hospital brand name alone.
Patient Consensus: Patients emphasize finding a surgeon who handles high volumes of glioma cases rather than just picking a famous hospital. They recommend requesting a second pathology review to ensure the treatment plan matches the specific tumor grade.
South Korea offers high-precision glioma treatments including heavy ion therapy, Gamma Knife radiosurgery, and natural killer cell immunotherapy. JCI-accredited centers in Seoul utilize molecular profiling to customize chemotherapy. These facilities combine advanced neurosurgery with targeted radiation to maximize survival rates for complex brain tumors.
Bookimed Expert Insight: While many countries offer standard neurosurgery, Seoul's major centers like Asan Medical Center and Severance Hospital handle massive volumes. Asan alone sees over 2,500 inpatients daily. This scale allows these institutions to maintain specialized neuro-oncology teams that focus exclusively on rare glioma subtypes. Choosing a high-volume academic center ensures access to molecular testing, which is now essential for selecting the correct chemotherapy protocol.
Patient Consensus: Patients emphasize that successful treatment revolves around finding a major Seoul hospital capable of coordinating surgery, radiation, and pathology together. Many note that quick access to molecular profiling at these centers was key to their personalized care plan.
Foreign patients can join glioma clinical trials in the Republic of Korea. Major academic centers like Severance Hospital and Asan Medical Center recruit international participants for Phase 2 and 3 studies. Eligibility depends on meeting strict medical criteria and often requires self-funding for experimental protocols.
Bookimed Expert Insight: Data shows Korean university hospitals manage massive patient volumes, with Severance Hospital seeing 1.6 million outpatients annually. This high turnover fuels rapid clinical trial recruitment and deep technical expertise. Patients should prioritize hospitals with recent Newsweek rankings and JCI accreditation to ensure the highest safety standards during experimental treatments.
Patient Consensus: Patients note that trial access is not open tourism and requires meeting strict research protocols. Frequent follow-up visits and imaging mean participants must plan for long-term stays in Seoul.
South Korea reports a 5-year survival rate of 40% to 49% for unspecified gliomas. This matches the survival rates found in the United States and Norway. Major Korean centers utilize Gamma Knife and craniotomy within JCI-accredited facilities to maintain these global outcomes.
Bookimed Expert Insight: Korea excels in high-volume surgical efficiency. Asan Medical Center alone handles over 65,000 operations annually. This massive scale often leads to faster scheduling than in Western Europe. Swift intervention is a critical factor for glioma outcomes.
Patient Consensus: Patients note that Korean hospitals provide world-class surgical care and coordinated oncology. Success is often attributed to the skill of high-volume neuro-oncology teams.
Surgical resection for glioma in South Korea typically occurs within 2 to 4 weeks after the initial neurosurgical consultation. Urgent cases involving significant edema or neurological deficits may be fast-tracked for admission. Treatment often begins immediately with steroids or anti-seizure medications to stabilize the patient before surgery.
Bookimed Expert Insight: Speed depends on choosing high-capacity centers. Severance Hospital and Asan Medical Center manage thousands of daily outpatients. Our data shows these facilities integrate pathology and neurosurgery rapidly. This coordination allows international patients to shave 10 or more days off the standard diagnostic timeline compared to smaller clinics.
Patient Consensus: Patients note that arriving with MRI disks rather than just reports speeds up the process. They emphasize that starting steroids immediately often provides quick relief while waiting for the surgical team to finalize the plan.
South Korean neuro-oncology departments provide professional medical interpreters for non-Korean-speaking patients. Major JCI-accredited facilities in Seoul offer dedicated international patient centers. These coordinators manage communication for complex glioma treatments, including Gamma Knife and craniotomy. Support typically covers English, Chinese, Arabic, and Russian.
Bookimed Expert Insight: Data shows that Severance and Asan Medical Center serve thousands of international patients annually. While many staff speak basic English, neuro-oncology discussions require high medical nuance. Choosing a JCI-accredited facility ensures that professional interpreters are available for critical surgical planning. This prevents reliance on basic terminology during complex brain tumor consultations.
Patient Consensus: Patients emphasize that contacting the international office weeks before arrival is essential. They note that having a medical interpreter present during the consent process provides vital peace of mind.
Proton therapy for glioma is primarily performed at major tertiary cancer centers in Seoul and Gyeonggi-do. Leading institutions include the National Cancer Center in Goyang and Samsung Medical Center. Both facilities utilize advanced proton beam technology to treat aggressive brain tumors like glioblastomas and astrocytomas.
Bookimed Expert Insight: While several hospitals like Seoul National University Hospital (SNUH) and Severance Hospital have top oncology ratings, proton therapy remains concentrated in specific centers. Asan Medical Center performs over 65,000 operations yearly. This high surgical volume often serves as the initial stage before radiation begins.
Patient Consensus: Patients note that major university hospitals require prior MRI and pathology records for review. They emphasize checking if a center’s neuro-oncology board approves proton therapy before traveling.
South Korean neurosurgeons treat glioma using maximal safe resection supported by neuronavigation and intraoperative MRI. Standard protocols include the Stupp regimen for glioblastoma, combining concurrent radiation with temozolomide chemotherapy. Leading Seoul hospitals often hold JCI accreditation and follow international neuro-oncology guidelines for personalised care.
Bookimed Expert Insight: South Korea's oncology landscape is defined by extreme surgical volume, which often leads to higher proficiency. For example, Seoul National University Bundang Hospital performs over 32,500 operations annually. This high-volume environment allows neurosurgical teams to refine techniques. They include laparoscopic-assisted or digital-guided resections. These may be less common in lower-volume Australian centres.
Patient Consensus: Patients note that surgery is prioritised whenever the tumour is accessible. This helps reduce mass before starting six-week radiation courses. Experiences suggest that supportive care and symptom tracking help manage quality of life. This is vital during the managed temozolomide cycles in South Korea.
Foreign patients in the Republic of Korea receive support through International Health Care Centers at major hospitals. These units manage medical translations, coordination, and administrative needs. Facilities such as Seoul National University Hospital (SNUH) provide 24/7 interpreter services. Some centres also offer free airport transfers and dedicated personal coordinators.
Bookimed Expert Insight: While many patients focus only on medical stats, the scale of Korean university hospitals provides a safety net. Asan Medical Center and Severance Hospital each manage over 40,000 operations annually. This high volume means their international departments are exceptionally well-equipped. They handle complex billing and foreign insurance logistics without delays.
Patient Consensus: Patients note that Korean nurses do not provide bedside caregiving. However, large Seoul hospitals easily arrange private caregivers for around 150,000 KRW daily. Many suggest obtaining all diagnostic reports in English immediately. This simplifies follow-up care with specialists back in Australia.
Republic of Korea offers treatment for high-grade gliomas using precision neurosurgery and targeted radiation. Centres in Seoul frequently use Gamma Knife radiosurgery and Tomotherapy to treat complex brain tumours. JCI-accredited hospitals integrate molecular diagnostics to personalise chemotherapy and surgical plans for glioblastoma cases.
Bookimed Expert Insight: A trend in Korean neuro-oncology is the heavy investment in precision hardware. This includes Tomotherapy and Gamma Knife devices. For example, Gangnam Severance Hospital uses two Tomotherapy devices specifically for brain and spine cancers. This suggests a focus on highly accurate radiation delivery. Such accuracy helps reduce recovery times for international patients.
Patient Consensus: Patients find that Korean cancer care is often just as good as in the US. At the same time, it is more affordable. They specifically highlight the professional test setups and high standards at Severance Hospital. These strengths are particularly noted for complex oncology cases.
Clinical trials in South Korea provide vital access to experimental therapies. They often treat recurrent glioblastoma and high-grade gliomas. These studies test methods including focused ultrasound to bypass the blood-brain barrier and gene therapies. Major Seoul centres lead these trials under Joint Commission International (JCI) accreditation.
Bookimed Expert Insight: Data shows South Korean centres like SNUH and Asan Medical Center handle massive volumes. They perform over 50,000 surgeries annually. This high throughput allows these hospitals to run complex trials that require large patient cohorts. Australian patients should note that centres like Seoul National University Hospital offer 24/7 interpreter services. This support helps international participants navigate the complex consent and monitoring requirements. These are inherent in clinical trials.
Patient Consensus: Patients see trials as a primary way to access new drugs when standard care fails. These include CAR-T or Optune devices. They emphasise checking if a tumour matches specific molecular criteria. They also highlight that trials can help cover high treatment costs.
South Korean glioma treatment plans rely on multidisciplinary reviews and Korean Society for Neuro-Oncology guidelines. Teams of neurosurgeons, oncologists, and pathologists integrate molecular pathology with advanced imaging. They use maximal safe resection and targeted radiosurgery. At JCI-accredited centres like Severance Hospital, this approach helps individualise care.
Bookimed Expert Insight: The 'President's choice' for medical care often indicates the highest national standard. Seoul National University Hospital (SNUH) is where the South Korean President receives treatment. Its neurosurgery department performs 3,800 interventions yearly. For glioma patients, this volume correlates with refined surgical protocols. Gamma Knife technology, in particular, reports a 90% success rate at SNUH.
Patient Consensus: Patients note that the best plan involves balancing aggressive tumour removal with daily function. In South Korea, families value the sequence of surgery followed by chemotherapy. It is tailored specifically to the tumour’s molecular markers.
South Korean glioblastoma treatment offers a median survival of 15 to 19 months through multimodal care. Specialist centres achieve a 30% survival rate at 2 years using JCI-accredited protocols. Fluorescence-guided surgery and Gamma Knife technology help neurosurgeons maximise tumour removal. They also spare healthy brain tissue.
Bookimed Expert Insight: South Korea's high-volume neurosurgery centres like Gangnam Severance Hospital perform over 1,300 surgeries annually. This intense specialisation leads to faster access to care. For example, Korea University Anam Hospital offers same-day consultation and admission for new oncology cases. This speed is vital for aggressive tumours where every day matters for prognosis.
Patient Consensus: Patients note that while the disease is aggressive, surgery is worth it when tumours are operable. Individual results often vary from general survival averages. So families emphasise focusing on surgery quality and close monitoring in South Korea.
Glioma support in South Korea combines multidisciplinary clinical care with dedicated international services. Major centres provide neurosurgeons, oncologists, and radiation specialists who coordinate treatment plans. Patients access tools like Gamma Knife and Tomotherapy alongside 24/7 interpreter services at JCI-accredited facilities like Severance Hospital.
Bookimed Expert Insight: Patient volume data suggests a massive expertise gap in Seoul. Seoul National University Hospital treats 30,000 international patients annually and conducts 3,800 neurosurgical procedures. This high volume allows teams to manage complex glioma cases that smaller regional centres rarely see. Australian patients should focus on these high-capacity university hospitals for better access to specialised neuro-oncology teams.
Patient Consensus: Patients emphasise the need for multidisciplinary teams covering rehab and palliative care to manage daily function. They also recommend securing full pathology reports early. This facilitates second opinions during the treatment process in South Korea.